Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited
STOCKHOLM, May 20, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment inJune 2022. T...
Animal health company Emollivet raises capital and strengthens team
GOTHENBURG, Sweden, March 15, 2022 /PRNewswire/ -- Emollivet, the animal health company that develops user-friendly skin care products for animals, is raising capital and recruiting key people. The new share issue, a rights issue to existing owners, amounts toSEK 5 million. On 3rd March, Emolliv...
Emollivet launches spray for equestrian pastern dermatitis
GOTHENBURG, Sweden, March 3, 2022 /PRNewswire/ -- Emollivet, a subsidiary of Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI), is now launching Emollivet COMBI: an antiseptic emollient spray for horses with pastern dermatitis. The product is released for the Swedish market and is availa...
Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis
STOCKHOLM, Jan. 26, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today reports that the first patients have been enrolled in a Phase III clinical study using AKP02 cutaneous spray (calcipotriol + betamethasone dipropionate 0.005 %/0.05 %) against mild to moderat...
Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris
STOCKHOLM, Dec. 17, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that it has initiated a preclinical program for a new drug candidate, AKP-08, focused on acne vulgaris (acne). The market for acne medicines amounts to about35 billion SEK per year, which togethe...
Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis
STOCKHOLM, Sept. 27, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company's Phase III clinical study of its drug candidate AKP02 for the treatment of psoriasis has been approved by the Indian Medical Products Agency and is ready to start...
Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70
STOCKHOLM, Sweden, July 2, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to re...
Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova
STOCKHOLM, April 23, 2021 /PRNewswire/ -- Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health mark...
Lipidor - update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis
STOCKHOLM, April 22, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North: LIPI) today provides an update on the planned Phase III study of the company's drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, Lipidor submitted an application to the Indian Med...
Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production
STOCKHOLM, Dec. 16, 2020 /PRNewswire/ -- Lipidor AB (Nasdaq First North: LIPI) announced today that the Company has signed a new cooperation agreement with Aurena Laboratories AB. Over a five-year period, Lipidor will invest up toSEK 15 million in the new collaboration. Under the agreement, Auren...
Lipidor Signs Agreement With CRO for Implementation of Phase III Clinical Study of Drug Candidate AKP-02 Against Psoriasis
STOCKHOLM, July 8, 2020 /PRNewswire/ -- Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to c...
Lipidor AB (publ) Formalizes Relationship With Subsidiary Emollivet AB Through License Agreement and Proposes Financing of Subsidiary
STOCKHOLM, Sweden, July 1, 2020 /PRNewswire/ -- Lipidor AB ("Lipidor" or the " Company") and its subsidiary Emollivet AB ("Emollivet") have formalized the relationship by entering into a licence agreement that regulates the right to Lipidor's patented AKVANO® technology. OnJune 30, Emollivet's Ext...
New Disinfection Spray From Lipidor and Aurena Laboratories
STOCKHOLM, March 4, 2020 /PRNewswire/ -- In connection with the ongoing outbreak of Covid-19, caused by the new coronavirus, demand for disinfectants has snowballed and many products have suffered from supply shortages. Lipidor (Nasdaq First North: LIPI) has previously developed a spray for hand ...
Lipidor Announces Positive Topline Results of AKP01 Phase III Clinical Study Using Calcipotriol Spray Against Psoriasis
STOCKHOLM, Jan. 24, 2020 /PRNewswire/ -- Lipidor AB (Nasdaq First North: LIPI) today reports positive topline results of its AKP01 Phase III clinical study, using calcipotriol spray against mild to moderate plaque psoriasis. The randomised 277-patient study achieved its primary endpoint demonstra...
Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO Spray (AKP01) Phase III Study Targeting Psoriasis
STOCKHOLM, Sept. 9, 2019 /PRNewswire/ -- Lipidor AB (publ) today reports that the last patient has been enrolled in the ongoing phase III study using calcipotriol spray against mild to moderate psoriasis. Results from the study are expected to be presented in December 2019. Lipidor has develope...
